SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2

SciBase's repurchase offer for TO 2 warrants was accepted for 418,150,952 warrants (≈83.9% of outstanding), with two warrants converting into one share, resulting in issuance of 209,075,476 new shares and an immediate dilution of about 33.5%. Post-offer outstanding TO 2 warrants total 80,383,883; the board intends to resolve a directed set-off issue around 27 January 2026 to subscribe these shares, which will be registered and delivered in connection with a previously resolved rights issue of ~SEK 83 million; share capital will increase by SEK 10,453,773.80.

Analysis

Market structure: The TO2 offer converts 418,150,952 warrants into 209,075,476 new shares (issuance ≈33.5% dilution) and leaves 80,383,883 warrants outstanding (~16.1% of original). Short-term winners are warrant holders who monetized into equity; incumbent shareholders are diluted and may face near-term selling pressure when shares register with the Rights Issue (linked to SEK 83m rights issue). Supply increases materially in late Jan 2026 (Set-off Issue expected ~27 Jan 2026) which should depress free-float and push spot volatility higher for 2–8 weeks around registration and trading windows.

Risk assessment: Tail risks include a failed rights-use case (SEK 83m insufficient to hit clinical/regulatory milestones), adverse FDI Act review blocking large foreign buyers, or accelerated warrant exercise creating >50% additional dilution; probability low-to-moderate but impact high (equity value down 30–70%). Immediate (days) risk: price gap on registration; short-term (weeks/months): liquidity-driven volatility; long-term (quarters/years): execution risk on Nevisense commercialization and reimbursement. Hidden dependency: market’s valuation hinges on how proceeds are allocated — R&D/CE-mark follow-through materially changes cash burn runway.

Trade implications: Direct play — establish a tactical long in SciBase Holding AB (Nasdaq First North) sized 1–3% NAV if post-registration price drops ≥20% from current levels, target +50% in 6–12 months if company funds commercialization; stop-loss 25% below entry. If share holds or rallies >10% into registration, avoid longs and consider a small short (0.5–1% NAV) versus a Swedish small-cap MedTech basket to hedge idiosyncratic dilution risk. Options: where available, prefer buying 3–6 month OTM put spreads to hedge downside around 27 Jan 2026 and selling short-dated implied-volatility elevated calls after registration to finance protection.

Contrarian angles: Consensus underestimates strategic value of SEK 83m — if allocated to a clear commercial launch (pilot roll-outs in EU) investor confidence could reverse quickly; acceptance of 83.9% suggests existing holders see long-term value, not pure exit. Reaction may be overdone if market prices only dilution and not improved runway — mispricing window likely 2–8 weeks post-registration. Historical parallels: small biotech rights + warrant conversions often produce a transient 20–40% drawdown followed by recovery upon milestone delivery; absence of such milestones is the key downside.

Key Decisions for Investors

• If SciBase (SciBase Holding AB, Nasdaq First North Growth Market) spot declines ≥20% on/after 27 Jan 2026 registration, accumulate a 1–3% NAV long position sized to target +50% in 6–12 months; set a stop-loss at -25% and review use of SEK 83m proceeds within 30 days of Rights Issue reporting.
• If shares rally >10% into the Set-off/registration date, establish a 0.5–1% NAV relative short versus a Swedish small-cap MedTech ETF or basket to hedge idiosyncratic dilution and execution risk; close within 4–8 weeks post-registration or on clear commercial milestone.
• Purchase 3–6 month OTM put spread (delta ~0.20–0.30) around 1–2 weeks before 27 Jan 2026 to protect existing exposure, financed by selling short-dated covered calls if liquidity permits; target cost <3% of position value and adjust if implied vol rises >30% above 60-day median.